How treatments affect aspects of life that are most important to patients is a priority for the US Food and Drug Administration (FDA) as it seeks ways to facilitate and accelerate drug development programmes. Deborah Komlos at Clarivate Analytics looks at how this topic was the basis of a public workshop held in July 2019, during which the FDA sought stakeholder input on clinical endpoints for trials in heart failure that could be used to support FDA approval of drugs.